What benzodiazepine‑receptor agonist (BzRA) hypnotic medications are recommended for short‑term treatment of insomnia, and what are their dosing regimens?

Benzodiazepine Receptor Agonist (BzRA) Medications for Insomnia

BzRA medications include both non-benzodiazepine "Z-drugs" (eszopiclone, zolpidem, zaleplon) and traditional benzodiazepines (temazepam, triazolam, estazolam, flurazepam), all of which are Schedule IV controlled substances recommended for short-term insomnia treatment. 1

Non-Benzodiazepine BzRAs ("Z-drugs")

Eszopiclone

• Dosing: 2-3 mg at bedtime for adults; 1 mg at bedtime for elderly/debilitated patients (max 2 mg) 1
• Indication: Sleep-onset and sleep maintenance insomnia 2
• Duration of action: Intermediate-acting 1
• Unique feature: No short-term usage restriction 1

Zolpidem

• Dosing: 10 mg at bedtime for adults (max 10 mg); 5 mg for elderly 1, 3
• Controlled-release formulation: 12.5 mg at bedtime for adults; 6.25 mg for elderly, debilitated, or hepatic impairment (swallow whole, do not crush) 1
• Indication: Primarily sleep-onset insomnia, though some effect on sleep maintenance 2, 3
• Duration of action: Short- to intermediate-acting 1

Zaleplon

• Dosing: 10 mg at bedtime (max 20 mg); 5 mg for elderly, debilitated, mild-moderate hepatic impairment, or with concomitant cimetidine 1
• Indication: Sleep-onset insomnia; can be used for middle-of-night awakening if at least 4 hours remain for sleep 1, 2
• Duration of action: Short-acting 1

Benzodiazepine BzRAs

Temazepam

• Dosing: 15-30 mg at bedtime for adults; 7.5 mg for elderly/debilitated 1
• Indication: Sleep-onset and sleep maintenance insomnia 2
• Duration of action: Short- to intermediate-acting 1

Triazolam

• Dosing: 0.25 mg at bedtime (max 0.5 mg); 0.125 mg for elderly/debilitated (max 0.25 mg) 1
• Indication: Sleep-onset insomnia 2
• Duration of action: Short-acting 1

Estazolam

• Dosing: 1-2 mg at bedtime; 0.5 mg for elderly/debilitated 1
• Duration of action: Short- to intermediate-acting 1

Flurazepam

• Dosing: 15-30 mg at bedtime; 15 mg for elderly/debilitated 1
• Duration of action: Long-acting 1
• Major caveat: Risk of residual daytime drowsiness; rarely prescribed due to extended half-life 1

Critical Safety Warnings

The FDA issued warnings regarding serious adverse effects with all BzRA hypnotics, including complex sleep-related behaviors (sleepwalking, sleep-eating, sleep-driving, sexual behavior while not fully awake). 1, 4

Essential Safety Precautions

• Administer on empty stomach to maximize effectiveness 1
• Not recommended during pregnancy or nursing 1
• Use caution with depression, compromised respiratory function (asthma, COPD, sleep apnea), or hepatic/heart failure 1
• Require downward dosage adjustment in elderly patients 1
• Safety/effectiveness not established in patients <18 years 1
• Additive psychomotor impairment with CNS depressants and/or alcohol 1
• Rapid discontinuation can produce withdrawal symptoms and rebound insomnia 1

Clinical Positioning

Short- to intermediate-acting BzRAs are recommended as first-line pharmacologic treatment for primary insomnia when behavioral interventions are unavailable or insufficient. 1

The American Academy of Sleep Medicine recommends the following treatment sequence: 1

1. Short-intermediate acting BzRAs as initial pharmacotherapy
2. Alternate BzRA if initial agent unsuccessful
3. Sedating antidepressants (especially with comorbid depression/anxiety)
4. Combined BzRA and sedating antidepressant

Non-benzodiazepine BzRAs may have less tendency for dependence and abuse compared to traditional benzodiazepines, though adverse effects remain problematic. 5, 6

Comparative Efficacy Considerations

• Non-benzodiazepines generally cause less disruption of normal sleep architecture than benzodiazepines 6
• Psychomotor and memory impairment may be less problematic with non-benzodiazepines, especially compared to longer-acting benzodiazepines 6
• Rebound insomnia and withdrawal symptoms occur less frequently with non-benzodiazepines 6

Duration of Treatment

BzRAs demonstrate efficacy for short-term treatment, but evidence for long-term efficacy is limited. 7

• Most FDA indications are for short-term, as-needed use 8
• Long-term prescribing should include consistent follow-up, ongoing effectiveness assessment, and monitoring for adverse effects 1
• Long-term administration may be nightly, intermittent (three nights per week), or as-needed 1